NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Biomarker Analysis of Central Nervous System Tumors

Terminated

Conditions: Central Nervous System Neoplasms
Neoplasms, Brain
Brain Cancer
Primary Brain Neoplasms
Cancer of the Brain

First Posted Date: 2016-02-26

Last Posted Date: 2019-11-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT02692898

Locations: 🇺🇸
National Cancer Institute (NCI), 9000 Rockville Pike, Bethesda, Maryland, United States

Molecular, Cellular, and Genetic Characterization of Human Adipose Tissue and Its Role in Metabolism

Recruiting

Conditions: Phenotyping
Brown Adipose Tissue (BAT) Physiology
Brown Adipocytes

First Posted Date: 2016-02-26

Last Posted Date: 2025-03-25

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 300

Registration Number: NCT02692885

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Chile Biliary Longitudinal Study

Completed

Conditions: Nutritional and Metabolic Diseases
Gallbladder Cancer

First Posted Date: 2016-02-26

Last Posted Date: 2021-03-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 4749

Registration Number: NCT02692911

Locations: 🇨🇱
Hospital Regional de Talca, Talca, Chile
🇨🇱
Universidad Catolica del Maule, Talca, Chile
🇨🇱
Hospital Regional de Temuco, Temuco, Chile

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

Phase 1

Completed

Conditions: Adult T-Cell Leukemia (ATL)
Peripheral T-Cell Lymphoma (PTCL)
Cutaneous T Cell Lymphoma (CTCL)
T-Cell Prolymphocytic Leukemia
T-Cell Lymphoma Relapsed

Interventions: Biological: IL-15 plus
Biological: alemtuzumab

First Posted Date: 2016-02-24

Last Posted Date: 2022-04-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 11

Registration Number: NCT02689453

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Recruiting

Conditions: Leukemia-Lymphoma, Adult T-Cell
Hodgkin Disease
Multiple Myeloma
Lymphoma, Non-Hodgkin
Non-Small Cell Lung Cancer

First Posted Date: 2016-02-15

Last Posted Date: 2025-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 500

Registration Number: NCT02682667

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1

Recruiting

Conditions: Chronic Graft vs Host Disease
Chronic Graft-Versus-Host Disease
Bronchiolitis Obliterans Syndrome

Interventions: Drug: MPH966

First Posted Date: 2016-02-01

Last Posted Date: 2025-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT02669251

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies

Phase 1

Completed

Conditions: Lymphoma, Non-hodgkins
Lymphoma, B-Cell

Interventions: Biological: Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2016-01-21

Last Posted Date: 2023-04-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT02659943

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

Phase 1

Active, not recruiting

Conditions: Kaposi Sarcoma

Interventions: Drug: liposomal doxorubicin
Drug: pomalidomide

First Posted Date: 2016-01-21

Last Posted Date: 2025-03-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 62

Registration Number: NCT02659930

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer
Prostate Neoplasms
Neoplasms, Prostatic

Interventions: Biological: PROSTVAC-V
Biological: PROSTVAC-F
Drug: Docetaxel

First Posted Date: 2016-01-08

Last Posted Date: 2024-08-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 74

Registration Number: NCT02649855

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Prostvac in Patients With Biochemically Recurrent Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Biological: PROSTVAC -V
Biological: PROSTVAC-F

First Posted Date: 2016-01-07

Last Posted Date: 2022-11-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 97

Registration Number: NCT02649439

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy